CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Report for D011658: Pulmonary Fibrosis NIH

(Synonyms: Pulmonary Fibrosi, Pulmonary Fibrosis)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (11)

Name (Synonyms) Correlation
drug699 Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) Wiki 0.58
drug1090 Sterile Normal Saline for Intravenous Use Wiki 0.58
drug751 Nintedanib 150 MG Wiki 0.58
drug719 N-acetylcysteine+ Fuzheng Huayu Tablet Wiki 0.58
drug559 IV Deployment Of cSVF In Sterile Normal Saline IV Solution Wiki 0.58
drug254 Centricyte 1000 Wiki 0.58
drug632 Liberase Enzyme (Roche) Wiki 0.58
drug720 N-acetylcysteine+Placebo Wiki 0.58
drug431 Favipiravir Wiki 0.18
drug505 Hydroxychloroquine Wiki 0.06
drug850 Placebo Wiki 0.05

Correlated MeSH Terms (10)

Name (Synonyms) Correlation
D011649 Pulmonary Alveolar Proteinosis NIH 0.58
D054990 Idiopathic Pulmonary Fibrosis NIH 0.58
D005355 Fibrosis NIH 0.41
D017563 Lung Diseases, Interstitial NIH 0.26
D008171 Lung Diseases, NIH 0.24
D011024 Pneumonia, Viral NIH 0.08
D003141 Communicable Diseases NIH 0.06
D007239 Infection NIH 0.04
D045169 Severe Acute Respiratory Syndrome NIH 0.03
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (4)

Name (Synonyms) Correlation
HP:0002206 Pulmonary fibrosis HPO 1.00
HP:0006517 Alveolar proteinosis HPO 0.58
HP:0006515 Interstitial pneumonitis HPO 0.26
HP:0002088 Abnormal lung morphology HPO 0.24

There are 3 clinical trials

Clinical Trials

1 A Randomized, Placebo-Controlled, Multi-Center Study on the Efficacy and Safety of Fuzheng Huayu on Pulmonary Fibrosis Due to 2019-nCoV

Inflammation is the early stage of fibrosis. Serious patients are more likely to develop into pulmonary fibrosis, which affects the recurrence of lung function or even threatens life and health. This study is planned to observe the efficacy and safety of Fuzheng Huayu tablets in the treatment of pulmonary fibrosis after COVID-19.

NCT04279197 Pulmonary Fibrosis Due to 2019-nCoV Drug: N-acetylcysteine+ Fuzheng Huayu Tablet Drug: N-acetylcysteine+Placebo
MeSH:Pulmonary Fibrosis Fibrosis
HPO:Pulmonary fibrosis

Primary Outcomes

Description: Evaluation of Pulmonary fibrosis Improvement. HRCT images are graded from 1 to 6, higher scores mean a worse outcome.

Measure: High-resolution computed tomography (HRCT) score

Time: Week 24

Description: Evaluation of Lung Function Improvement

Measure: Lung function including FVC, FVC as a percentage of projected value and DLco

Time: Week 24

Secondary Outcomes

Description: Times of acute exacerbations during treatment

Measure: Times of acute exacerbation

Time: Week 24

Description: Measured by a 6-minute walking test

Measure: Six-minute walk distance

Time: Week 24

Description: Using the scale revised by British modified Medical Research Council (MMRC) which divided patients into five degrees.Higher scores mean a worse outcome.

Measure: Dyspnea Scores

Time: Week 24

Description: Evaluation of Pulmonary fibrosis Improvement on CT which is calculated by formula.

Measure: Composite physiological index

Time: Week 24

2 Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection

COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality. A short review includes: - Early December, 2019 - A pneumonia of unknown cause was detected in Wuhan, China, and was reported to the World Health Organization (WHO) Country Office. - January 30th, 2020 - The outbreak was declared a Public Health Emergency of International Concern. - February 7th, 2020 - 34-year-old Ophthalmologist who first identified a SARS-like coronavirus) dies from the same virus. - February 11th, 2020 - WHO announces a name for the new coronavirus disease: COVID-19. - February 19th, 2020 - The U.S. has its first outbreak in a Seattle nursing home which were complicated with loss of lives.. - March 11th, 2020 - WHO declares the virus a pandemic and in less than three months, from the time when this virus was first detected, the virus has spread across the entire planet with cases identified in every country including Greenland. - March 21st, 2020 - Emerging Infectious Disease estimates the risk for death in Wuhan reached values as high as 12% in the epicenter of the epidemic and ≈1% in other, more mildly affected areas. The elevated death risk estimates are probably associated with a breakdown of the healthcare system, indicating that enhanced public health interventions, including social distancing and movement restrictions, should be implemented to bring the COVID-19 epidemic under control." March 21st 2020 -Much of the United States is currently under some form of self- or mandatory quarantine as testing abilities ramp up.. March 24th, 2020 - Hot spots are evolving and identified, particularly in the areas of New York-New Jersey, Washington, and California. Immediate attention is turned to testing, diagnosis, epidemiological containment, clinical trials for drug testing started, and work on a long-term vaccine started. The recovering patients are presenting with mild to severe lung impairment as a result of the viral attack on the alveolar and lung tissues. Clinically significant impairment of pulmonary function appears to be a permanent finding as a direct result of the interstitial lung damage and inflammatory changes that accompanied. This Phase 0, first-in-kind for humans, is use of autologous, cellular stromal vascular fraction (cSVF) deployed intravenously to examine the anti-inflammatory and structural potential to improve the residual, permanent damaged alveolar tissues of the lungs.

NCT04326036 Pulmonary Alveolar Proteinosis COPD Idiopathic Pulmonary Fibrosis Viral Pneumonia Coronavirus Infection Interstitial Lung Disease Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) Device: Centricyte 1000 Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution Drug: Liberase Enzyme (Roche) Drug: Sterile Normal Saline for Intravenous Use
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia, Viral Lung Diseases Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Lung Diseases, Interstitial Pulmonary Alveolar Proteinosis
HPO:Abnormal lung morphology Alveolar proteinosis Interstitial pneumonitis Interstitial pulmonary abnormality Pulmonary fibrosis

Primary Outcomes

Description: Reporting of Adverse Events or Severe Adverse Events Assessed by CTCAE v4.0

Measure: Incidence of Treatment-Emergent Adverse Events

Time: 1 month

Secondary Outcomes

Description: High Resolution Computerized Tomography of Lung (HRCT Lung) for Fluidda Analysis comparative at baseline and 3 and 6 months post-treatment comparative analytics

Measure: Pulmonary Function Analysis

Time: baseline, 3 Month, 6 months

Description: Finger Pulse Oximetry taken before and after 6 minute walk on level ground, compare desaturation tendency

Measure: Digital Oximetry

Time: 3 months, 6 months

3 Efficacy and Safety of Nintedanib Ethanesulfonate Soft Capsule in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID-9(COVID 19) : a Single-center, Randomized, Placebo-controlled Study

This center intends to conduct a single-center, randomized, placebo-controlled study to evaluate the effectiveness and safety of Nintedanib ethanesulfonate soft capsule in the treatment of pulmonary fibrosis in patients with moderate to severe COVID-19.

NCT04338802 COVID-19 Nintedanib Safety Effect of Drugs Drug: Nintedanib 150 MG Other: Placebo
MeSH:Pulmonary Fibrosis
HPO:Pulmonary fibrosis

Primary Outcomes

Description: Changes in forced vital capacity (FVC) after treatment compared to baseline.

Measure: Changes in forced vital capacity (FVC)

Time: 8 weeks

Secondary Outcomes

Description: Changes incarbon monoxide dispersion (DLco%) after treatment compared to baseline.

Measure: Changes in carbon monoxide dispersion (DLco%)

Time: 8 weeks

Description: Changes in the six-minute walk test (6MWT) after treatment compared to baseline.

Measure: Changes in the six-minute walk test (6MWT)

Time: 8 weeks

Description: Changes in High resolution CT score after treatment compared to baseline.The minimum and maximum values are 0 and 25 , and higher scores mean a worse outcome. As for the score, it is the expected value and will be determined according to the actual result

Measure: Changes in High resolution CT score

Time: 8 weeks

HPO Nodes